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Summary
Background Pulsed-wave ultrasound increases the exposure of an intracranial thrombus to alteplase (recombinant 
tissue plasminogen activator), potentially facilitating early reperfusion. We aimed to ascertain if a novel operator-
independent transcranial ultrasound device delivering low-power high-frequency ultrasound could improve functional 
outcome in patients treated with alteplase after acute ischaemic stroke.
Methods We did a multicentre, double-blind, phase 3, randomised controlled trial (CLOTBUST-ER) at 76 medical 
centres in 14 countries. We included patients with acute ischaemic stroke (National Institutes of Health Stroke Scale 
score ≥10) who received intravenous thrombolysis (alteplase bolus) within 3 h of symptom onset in North America and 
within 4·5 h of symptom onset in all other countries. Participants were randomly allocated (1:1) via an interactive web 
response system to either active ultrasound (2 MHz pulsed-wave ultrasound for 120 min [sonothrombolysis]; 
intervention group) or sham ultrasound (control group). Ultrasound was delivered using an operator-independent 
device, which had to be activated within 30 min of the alteplase bolus. Participants, investigators, and those assessing 
outcomes were unaware of group assignments. The primary outcome was improvement in the modified Rankin Scale 
score at 90 days in patients enrolled within 3 h of symptom onset, assessed in the intention-to-treat population as a 
common odds ratio (cOR) using ordinal logistic regression shift analysis. This trial is registered with ClinicalTrials.gov, 
number NCT01098981. The trial was stopped early by the funder after the second interim analysis because of futility.
Findings Between August, 2013, and April, 2015, 335 patients were randomly allocated to the intervention group and 
341 patients to the control group. Compared with the control group, the adjusted cOR for an improvement in modified 
Rankin Scale score at 90 days in the intervention group was 1·05 (95% CI 0·77–1·45; p=0·74). 51 (16%) of 317 patients 
in the intervention group and 44 (13%) of 329 patients in the control group died (unadjusted OR 1·24, 95% CI 0·80–1·92; 
p=0·37) and 83 (26%) and 79 (24%), respectively, had serious adverse events (1·12, 0·79–1·60; p=0·53). 
Interpretation Sonothrombolysis delivered by an operator-independent device to patients treated with alteplase after 
acute ischaemic stroke was feasible and most likely safe, but no clinical benefit was seen at 90 days. Sonothrombolysis 
could be further investigated either in randomised trials undertaken in stroke centres that are dependent on patient 
transfer for endovascular reperfusion therapies or in countries where these treatments cannot yet be offered as the 
standard of care.
Funding Cerevast Therapeutics.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Introduction
Intravenous alteplase (recombinant tissue plasminogen 
activator) is the only approved medical reperfusion 
treatment for acute ischaemic stroke1,2 and should be 
initiated as early as possible for maximum benefit.3 Yet, 
half of patients remain disabled or die despite medical 
treatment because of the initial severity of ischaemic insult 
and inadequate response to intravenous thrombolysis.4,5 
Therefore, amplification of alteplase effectiveness in 
thrombus dissolution remains an important goal for 
future development of more effective medical stroke 
treatments, even in the era of mechanical thrombectomy, 
because endovascular reperfusion therapies are not readily 
available in most stroke centres around the world.6
Findings of a phase 2 randomised controlled trial7 of 
2 MHz diagnostic ultrasound equipment (transcranial 
Doppler), and meta-analyses8,9 of similar studies, showed 
that ultrasound aimed at the residual flow and thrombus 
interface can at least double the chance of early recanal-
isation. Sono thrombolysis was also associated with a 
higher likeli hood of favourable functional outcome in the 
subgroup of patients with pretreatment scores of 10 points 
or more on the National Institutes of Health Stroke Scale 
(NIHSS).10 However, a major obstacle for emergency 
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doctors, neurologists, and health professionals, which 
restricts use of diagnostic ultrasound equipment in acute 
ischaemic stroke, is operator dependency.11 In previous 
work, we developed a novel hands-free thera peutic device 
with operator-independent targeting of the intracranial 
vessels, which has been shown to be safe in early-phase 
clinical trials.12,13 On the basis of this previous work, 
we undertook the Combined Lysis of Thrombus using 
Ultrasound and Systemic Tissue Plasminogen Activator 
for Emergent Revascularization (CLOTBUST-ER) trial—a 
phase 3 randomised controlled trial of sono thrombolysis 
in patients with acute ischaemic stroke. Our objective 
was to establish the safety and therapeutic efficacy of 
our operator-independent device in combination with 
intravenous alteplase to improve functional outcome, 
compared with intravenous alteplase alone, in patients 




We did a multicentre, double-blind, sham-controlled, 
phase 3, randomised trial (CLOTBUST-ER) at 76 medical 
centres in 14 countries. 40 centres were based in Europe, 
31 in North America, three in Australia, and two in Asia. 
A list of centres that enrolled patients in CLOTBUST-ER 
is available in the appendix. Details of methods used 
have been published elsewhere.14 The study was under-
taken and reported with fidelity to the study protocol.14 
The trial was approved by the institutional review board 
at every site or national ethics committee, as required.
Participants
We enrolled patients aged 18–80 years with acute 
ischaemic stroke who had baseline NIHSS scores of 
10 points or more and who received intravenous alteplase 
within a 3 h treatment window in North America or within 
a 4·5 h treatment window in other participating countries, 
as per national approval labels.14 The NIHSS cutoff 
was selected on the basis of a sensitivity analysis of 
phase 2 trial data,10,14 which indicated that the beneficial 
effect of sonothrombolysis was amplified in subgroups of 
patients with acute ischaemic stroke with NIHSS scores 
of 10 points or more. All patients were independently 
functioning in the community immediately before their 
stroke, with a premorbid modified Rankin Scale score of 
0–1. Patients were included irrespective of the antici-
pated stroke localisation (anterior or posterior circulation). 
Written informed consent was obtained from the patient 
or a legal representative before enrolment. A detailed 
list of inclusion and exclusion criteria (including planned 
endovascular reperfusion procedures) has been pub-
lished14 and is available in the appendix.
Randomisation and masking
We randomly allocated patients in a 1:1 ratio using web-
based central randomisation14 and random permuted 
blocks stratified by site (random block size of two, four, or 
six) to either active ultrasound (intervention group) or 
sham ultrasound (control group). Every patient was 
assigned a unique site-specific identification number after 
providing informed consent. Patients were randomised 
either before or after administration of the alteplase bolus, 
with the hands-free therapeutic device to be activated 
within 30 min of the alteplase bolus. The device was 
programmed based on a randomisation code that main-
tained masking of treating doctors, patients, and the 
funder to active versus sham assignments. The interactive 
web response system for randomisation was provided by 
ITClinical (Lisbon, Portugal). The system was audited 
and met all required Good Clinical Practice compli-
ance requirements. Masking was achieved through an 
algorithm that determined whether “A” setting de livered 
active insonation and “B” delivered sham (control) 
insonation, or the reverse. The interactive web response 
system was programmed to mask the A or B assignments; 
Research in context
Evidence before this study
We searched MEDLINE and Scopus up to Nov 17, 2018, 
without language or any other restrictions, for randomised 
controlled trials of ultrasonography to enhance the 
thrombolytic activity of alteplase (recombinant 
tissue plasminogen activator), referred to as 
sonothrombolysis, using the keywords “sonothrombolysis”, 
“ultrasound-enhanced thrombolysis”, “ischemic stroke”, and 
“clinical trial”. Our search identified six small-scale (phase 2) 
randomised clinical trials comparing sonothrombolysis with 
intravenous alteplase or standard-of-care treatment. 
However, our search found that no large-scale (phase 3) 
randomised controlled trials using an operator-independent 
transcranial ultrasound device delivering sonothrombolysis 
had been undertaken.
Added value of the study
Exposure of patients with acute ischaemic stroke to low-power 
high-frequency ultrasound using an operator-independent 
device, after receiving standard-of-care treatment with 
alteplase, was found to be feasible and most likely safe, but no 
clinical benefit was seen after 90 days.
Implications of all available evidence
Sonothrombolysis with low-power high-frequency ultrasound 
seems to be safe but offers no clinical benefit in patients with 
acute ischaemic stroke. The potential efficacy of 
sonothrombolysis could be further investigated either in stroke 
centres that are dependent on patient transfer for endovascular 
reperfusion therapies or in countries where these treatments 
cannot yet be offered as standard of care.
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there fore, no user could see which assign ment patients 
were given. The success of masking procedures was not 
assessed.
Procedures
All eligible patients received standard-of-care treat-
ment, which included full-dose intravenous alteplase 
(0·9 mg/kg; 90 mg maximum; 10% bolus followed by 90% 
intravenous infusion over 60 min). The headframe (for 
delivery of the ultrasound assignment) had to be placed on 
all patients before or shortly after the alteplase bolus, so as 
not to delay administration, and had to be activated within 
30 min of the alteplase bolus to achieve maximum overlap 
between exposure to the device and alteplase infusion. All 
patients—regardless of device activation time—were 
required to wear the headframe for a total of 120 min. 
Devices were equipped with a timer showing completion 
of 120 min exposure and a pause button in case the patient 
had to have a repeat CT scan done as part of standard-of-
care treatment. Interrupt ion time to deliver standard-of-
care treatment requiring temporary device removal could 
not exceed 15 min. A training video was created before 
study initiation. All site investigators watched the training 
video and prac tised assembly and placement of devices 
under direct supervision of trained clinical monitors in 
each country. All sites were trained before site initiation. 
Moreover, all new investigators were required to undergo 
similar training during the trial. Finally, all global and 
local investigator meetings had training sessions for new 
and existing sites.
In accordance with parameters mandated by the US 
Food and Drug Administration (FDA) for currently 
approved and marketed transcranial Doppler diagnostic 
ultrasound devices,15 the intervention group received 
2 MHz pulsed-wave transcranial ultrasound for 120 min 
(total average power 32 mW; maximum spatial peak 
temporal average intensity 207 mW/cm² ; pulse repetition 
frequency 8·3 kHz; pulse duration 5 μs). The control 
group received sham (inactive) ultrasound for 120 min. 
Details of the operator-independent device, vessel target-
ing without imaging or Doppler echolocation, safety test-
ing, and phase 2 functional outcomes data have been 
published elsewhere.12,13
Investigators obtained NIHSS scores before treatment, 
2 h and 24 h after treatment, on either day 7 or at discharge 
from an acute facility to home (if the patient was 
discharged before day 7), and at day 90. Modified Rankin 
Scale scores were recorded on either day 7 or at discharge 
and at day 90. Substantial neurological worsening—
defined as a total increase in NIHSS score by 4 points or 
more from the best score at any time during the first 
24 h after alteplase bolus—required a non-contrast CT to 
rule out symptomatic intracranial haemorrhage. Routine 
post-stroke imaging was not mandatory but was done 
at all participating centres as part of standard-of-care 
treatment for acute ischaemic stroke.
Outcomes
The primary outcome was improvement (defined as a 
1-point decrease across all scale scores [shift analysis]) in 
modified Rankin Scale score16 at 90 days (range 80–100) 
after randomisation, for all participants enrolled within 
3 h of onset of stroke symptoms (according to FDA regula-
tory requirements), as assessed by cumulative ordinal 
logis tic regression analysis in the intention-to-treat popu-
lation (which included all enrolled patients). This analysis 
was repeated as a secondary outcome for all patients who 
were enrolled within 4·5 h, which was a criterion for 
enrolment worldwide (global outcome).14 Other secondary 
efficacy endpoints included patients with dichotomous 
modified Rankin Scale scores of 0–1 and 0–2 at 90 days, 
dram atic clinical recovery at 120 min, clinical recovery at 
24 h, neurological improvement at 24 h, neurologi cal 
deterioration at 24 h, duration of hospital stay until 
discharge, independent functional outcome at 90 days, 
NIHSS score at day 7, NIHSS score at day 90, and modified 
Rankin Scale score at 7 days or discharge.14 Secondary 
efficacy outcomes were assessed both in participants 
enrolled within 3 h of onset of stroke symptoms (ref-
erred to as US outcomes) and in those enrolled within 
4·5 h (global outcomes). Dramatic clinical recovery 
assessed at 120 min (range 105–135) after headframe 
activation was defined as either a reduction in NIHSS 
score of 10 points or more compared with pretreatment 
or a total NIHSS score of 3 points or less. Clinical recovery 
assessed at 24 h (range 22–26) after headframe activation 
was defined as either a reduction in NIHSS score of 
10 points or more compared with pretreatment or a total 
NIHSS score of 3 points or less. Neurological improvement 
assessed at 24 h (range 22–26) after headframe activation 
was defined as a reduction in NIHSS score of 5 points 
or more compared with pretreatment. Neuro logical deter-
ioration assessed at 24 h (range 22–26 h) after headframe 
activa tion was defined as an increase in NIHSS score of 
Figure 1: Trial profile
*Treatment was never started, or patient received wrong treatment (crossover). †Recorded insonation time was 
<105 min (instead of the projected 120 min).
676 patients randomised and received 
         intravenous alteplase
335 allocated intervention (active ultrasound)
         316 received intervention
            19 did not receive intervention*
341 allocated control (sham ultrasound)
         330 received control
            11 did not receive control*
335 included in intention-to-treat 
         analysis
341 included in intention-to-treat 
         analysis
28 lost to follow-up
23 discontinued
      intervention†
35 lost to follow-up
14 discontinued
      intervention†
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4 points or more compared with pretreatment.14 Inde-
pendent functional outcome assessed at 90 days (range 
80–100) was defined as either a modified Rankin Scale 
score of 0–1 for patients with a pretreatment NIHSS 
score of 10–14 and a modified Rankin Scale score of 
0–2 for patients with a pretreatment NIHSS score greater 
than 14.
Safety outcomes were assessed in the safety population, 
which included all patients who received any part of 
the treatment and provided at least one assessment of 
safety. Safety outcomes included symptomatic intracranial 
haemorrhage within 24 h of alteplase bolus and an overall 
analysis of adverse events, as described elsewhere.14 
Symptomatic intracranial haemorrhage was defined per 
study protocol as neuro logical deterioration (a reduction 
in NIHSS score of 4 points or more compared with best 
previous exami nation) within 24 h after alteplase bolus, 
with documented parenchymal haemorrhage type 2 or 
remote parenchymal haemorrhage type 2. Digital images 
of all intracranial bleeds within 24 h that were associated 
with neurological deterioration were sent to a central 
imaging core laboratory (Foothills Medical Centre, 
Calgary, AB, Canada) for independent adjudication. We 
also assessed patients with symptomatic intracranial 
haemorrhage within 36 h,17 applying the definition and 
adjudication process used for the 24 h period to all 
neurological deteriorations reported within 36 h of 
the alteplase bolus.1 Three patients with symptomatic 
intra cranial haemorrhage were diagnosed by local 
investigators, without central adjudica tion, because of 
early trial termination by the funder. We included these 
cases in the final group with symptomatic intracranial 
haemorrhage, assuming the worst-case scenario. Intra-
cranial haemorrhage that was not associated with 
neuro logical deterioration of 4 points or more on the 
NIHSS scale were subsequently classified as asympto-
matic intracranial haemorrhage.
All prespecified adverse events ,14 coded and tabulated by 
MedDRA System Organ Class, were reported by clinical 
investigators at partici pating centres who were masked to 
treatment assign ments. Adverse events were reviewed 
and adjudicated by an independent panel within the Data 
Safety Monitoring Board, who also were unaware of 
treatment assignments. If a discrepancy arose between 
the adjudi cation panel and the clinical investigator, the 
adjudication panel’s deter mination was final. Brain 
herniation, cerebral oedema, and midline shift were not 
prespecified adverse events of our study and, therefore, 
were not centrally adjudicated. Information for these 
adverse events was gathered based on onsite clinical and 
radiology reports. We used no standardised definition for 
these adverse events. All adverse events were presented in 
de scending fre quency. Adverse events were also tabulated 
by severity and relation to the investigational device.14 
Death from any cause within 90 days of treatment and 
deaths due to adverse events were also summarised by 
treatment group.
Statistical analysis
Our prespecified statistical analysis plan, power estima-
tions, and planned interim analyses have been published 
elsewhere,14 and are available in the appendix. Interim 
analyses assessing the primary outcome were sched-
uled after approximately a third and two-thirds of modi-
fied Rankin Scale scores at 90 days were available. 
O’Brien-Fleming boundaries for the group sequential 
design, with 90% power and testing at approximately a 
third and two-thirds of patients, implied critical values of 
p=0·0003525 at the first interim analysis, p=0·0120085 at 
the second interim analysis, and p=0·0462386 at the final 
analysis. Moreover, a conditional power futility analysis 





Age (years) 70 (60–76) 70 (60–75)
Sex
Male 187 (56%) 206 (60%)
Female 148 (44%) 135 (40%)
Ethnic origin
White 261 (78%) 270 (79%)
Black or African-American 18 (5%) 17 (5%)
Hispanic-Latino 37 (11%) 33 (10%)
Asian 12 (4%) 13 (4%)
South Asian or Indian 0 1 (<1%)
Filipino 0 1 (<1%)
American Indian or 
Alaskan Native
0 2 (1%)
Unknown 7 (2%) 4 (1%)
NIHSS score 15 (11–18) 14 (11–18)
Hypertension 196 (59%) 213 (62%)
Diabetes mellitus 75 (22%) 80 (23%)
Atrial fibrillation 62 (19%) 54 (16%)
Prestroke modified Rankin 
Scale score 0–1
334 (100%) 339 (100%)
Systolic blood pressure 
before alteplase bolus 
(mm Hg)*
150·3 (20·2) 150·3 (20·4)
Diastolic blood pressure 
before alteplase bolus 
(mm Hg)†
81·7 (13·2) 81·8 (13·2)
Serum glucose before 
alteplase bolus (mg/dL)
139·6 (53·0) 137·5 (53·4)
Time from symptom onset 
to alteplase bolus (min)
117·0 (95·0–156·0) 126·0 (96·0–165·0)
Alteplase bolus within 3 h of 
symptom onset
279 (83%) 285 (84%)
Time from symptom onset to 
headframe activation (min)
136·0 (117·0–175·0) 148·0 (115·0–185·5)
Time from alteplase bolus to 
headframe activation (min)
20·0 (13·0–27·0) 20·0 (13·0–25·0)
Data are median (IQR), mean (SD), or n (%). NIHSS=National Institutes of Health 
Stroke Scale. *Data missing for nine patients in the intervention group and for 
13 patients in the control group. †Data missing for eight patients in the 
intervention group and for 13 patients in the control group.
Table 1: Baseline characteristics
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Safety Monitoring Board, at which time the study would 
stop should the conditional power fall below 15%.
Analyses reported here were undertaken in the 
intention-to-treat population using a program written 
in Matlab version R2018b, and one master datafile was 
generated. All further statistical analyses were done in 
R version 3.4, running under an R Studio environment, 
and primary outcomes were cross-checked in the Matlab 
environment. All planned statistical analyses were done 
before unblinding of data.
The primary outcome was specified as the propor-
tional odds logistic regression (polr command in R) over 
the 90-day modified Rankin Scale score distribution 
(scores range from 0 to 6), after combining data for 
grades 5 and 6.14 By doing univariate logistic regressions 
for each of the six groupings (ie, 0, 1, 2, 3, 4, and 5–6), we 
noted that the odds ratios (ORs) cluster around one, with 
negligible differences attributed to random variation, 
giving credit to the hypothesis of proportional odds 
across the groupings of the modified Rankin Scale score. 
Further, we did two imputation analyses on the primary 
endpoint. Missing modified Rankin Scale scores were 
estimated using multiple imputation methodology18 in 











Modified Rankin Scale score at 90 days in 
patients enrolled within 3 h of symptom 
onset
3·0 (1·0–4·0) 3·0 (1·0–4·0) 1·03 (0·76–1·40)† 0·84 1·05 (0·77–1·45)† 0·74
Secondary outcomes in patients enrolled within 4·5 h of symptom onset (global outcomes)*
Modified Rankin Scale score at 90 days 3·0 (1·0–4·0) 3·0 (1·0–4·0) 1·00 (0·76–1·32)† 0·99 1·06 (0·80–1·42)† 0·67
Modified Rankin Scale score at 7 days or 
discharge
3·0 (2·0–4·0) 4·0 (1·0–5·0) 0·99 (0·75–1·31)† 0·97 1·10 (0·82–1·47)† 0·51
Modified Rankin Scale score of 0–1 at 
90 days
96/307 (31%) 98/306 (32%) 0·97 (0·69–1·36)† 0·86 1·05 (0·73–1·52)† 0·79
Modified Rankin Scale score of 0–2 at 
90 days
149/307 (49%) 142/306 (46%) 1·09 (0·79–1·50)† 0·63 1·25 (0·87–1·79)† 0·22
Independent functional outcome at 
90 days
113/307 (37%) 114/306 (37%) 0·98 (0·71–1·36) 0·93 1·07 (0·75–1·51) 0·72
Dramatic clinical recovery at 120 min 60/323 (19%) 65/330 (20%) 0·93 (0·63–1·37) 0·77 0·95 (0·63–1·43) 0·80
Clinical recovery at 24 h 100/313 (32%) 116/322 (36%) 0·83 (0·60–1·16) 0·31 0·88 (0·63–1·24) 0·46
Neurological improvement at 24 h 176/313 (56%) 180/322 (56%) 1·01 (0·74–1·39) 0·94 1·08 (0·78–1·49) 0·66
Neurological deterioration at 24 h 29/313 (9%) 19/322 (6%) 1·63 (0·89–2·97) 0·13 1·47 (0·80–2·75) 0·21
NIHSS at 7 days 5 (1–12) 6 (1–12) ·· 0·82 ·· ··
NIHSS at 90 days 2 (1–6) 2 (1–5) ·· 0·68 ·· ··
Duration of hospital stay until discharge 
(days)
7 (5–12) 7 (4–11) ·· 0·48 ·· ··
Secondary outcomes in patients enrolled within 3 h of symptom onset (US outcomes)‡
Modified Rankin Scale score at 7 days or 
discharge
3·0 (2·0–4·0) 4·0 (1·0–5·0) 1·03 (0·76–1·40)† 0·83 1·09 (0·80–1·50)† 0·58
Modified Rankin Scale score of 0–1 at 
90 days
82/255 (32%) 78/254 (31%) 1·07 (0·73–1·55)† 0·77 1·16 (0·77–1·75)† 0·48
Modified Rankin Scale score of 0–2 at 
90 days
127/255 (50%) 118/254 (47%) 1·14 (0·81–1·62)† 0·48 1·27 (0·85–1·89)† 0·24
Independent functional outcome at 
90 days
96/255 (38%) 93/254 (37%) 1·04 (0·73–1·50) 0·85 1·11 (0·76–1·63) 0·58
Dramatic clinical recovery at 120 min 58/269 (22%) 60/279 (22%) 0·99 (0·66–1·49) >0·99 0·99 (0·65–1·52) 0·97
Clinical recovery at 24 h 83/261 (32%) 102/271 (38%) 0·77 (0·54–1·10) 0·17 0·79 (0·54–1·15) 0·22
Neurological improvement at 24 h 148/261 (57%) 154/271 (57%) 0·99 (0·71–1·40) >0·99 1·04 (0·73–1·49) 0·83
Neurological deterioration at 24 h 23/261 (9%) 17/271 (6%) 1·44 (0·75–2·77) 0·32 1·37 (0·70–2·71) 0·36
NIHSS at 7 days 5 (1–12) 6 (1–12) ·· 0·80 ·· ··
NIHSS at 90 days 2 (0–6) 2 (0–5) ·· 0·84 ·· ··
Duration of hospital stay until discharge 
(days)
7 (5–12) 7 (4–11) ·· 0·60 ·· ··
Data are median (IQR) or n/N (%). NIHSS=National Institutes of Health Stroke Scale. OR=odds ratio. *Analyses were done in the intention-to-treat population, comprising 
335 patients allocated to the intervention group and 341 allocated to the control group. †Data for modified Rankin Scale score outcomes are common odds ratios. 
‡279 patients from the intervention group and 285 from the control group were enrolled within 3 h of symptom onset. 
Table 2: Primary and secondary efficacy outcomes
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90-day modified Rankin Scale score, as prespecified in 
our statistical analysis protocol (ie, baseline NIHSS 
score, NIHSS score at 24 h, or modified Rankin Scale 
score at day 7 or discharge, along with assignment to 
treatment or control). In the second analysis, missing 
modified Rankin Scale scores were imputed to the worst 
case (eg, modified Rankin Scale score of 6). For the 
primary outcome of interest, we analysed alterations in 
the distribution of patients over the entire range of the 
six groupings of modified Rankin Scale scores (shift 
analysis—ie, analysis over ranks) and reported the 
corresponding common odds ratios (cORs) to express 
the change in odds for each unit (1-point) decrease in 
modified Rankin Scale score between the two groups. 
Unadjusted and adjusted analyses are reported separ-
ately. Both unadjusted and adjusted statistical analyses for 
secondary endpoints were prespecified. The unadjusted 
approach was the primary analytical approach whereas the 
adjusted approach served as a secondary analysis. Pre-
specified secondary efficacy outcomes were tested in 
unadjusted analyses with Fisher’s two-sided test of 
proportions, and CIs were provided according to the 
methodology of Bland and Altman.19 Prespecified safety 
outcomes were also tested using Fisher’s two-sided test of 
proportions. Adjustment was done in terms of baseline 
NIHSS score, age, baseline serum glucose, and time 
to alteplase bolus. These factors were chosen post hoc 
by the steering committee before unmasking of data. 
Adjustment for these factors was applied uniformly for all 
safety and efficacy outcomes. In all analyses, no allowance 
for multiplicity was made. To allow for the interim 
analyses, α spend adjustment was not done while calculat-
ing p values in all analyses. Also, point estimates were 
crude and not bias-adjusted for the interim analyses.
This trial is registered with ClinicalTrials.gov, number 
NCT01098981.
Role of the funding source
The funder contributed to study design, data monitoring, 
and database maintenance. The funder had no role in 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data in 
the study. The steering committee of CLOTBUST-ER, 
which included representatives of the funder, had final 
responsi bility for the decision to submit for publication.
Results
Between August, 2013, and April, 2015, 676 participants 
underwent randomisation, of whom 335 were allocated 
to the intervention group (active ultrasound) and 341 to 
the control group (sham ultrasound); these patients 
comprised the intention-to-treat population (figure 1). 
Patients assigned to the intervention and control groups 
did not differ in any baseline characteristics (table 1). The 
median elapsed time from alteplase bolus to headframe 
activation was similar in the intervention group (20 min 
[IQR 13–27]) and control group (20 min [13–25]).
CLOTBUST-ER was stopped early because of futility, 
according to prespecified stopping rules, by the Data 
Safety and Monitoring Board after the per-protocol defined 
second interim analysis, at which time two-thirds of 90-day 
modified Rankin Scale scores were available. The results 
of the first and second interim analyses of the primary 
outcome are available in the appendix. Patients who were 
enrolled in the study at the time of the futility determination 
were followed up until 90 days after the alteplase bolus by 
site investigators, despite discontinu ation of the study by 
the funder. We present here the results for the total sample 
of patients randomised in CLOTBUST-ER.
Among participants randomised within 4·5 h of 
symptom onset, 28 patients in the intervention group 
and 35 patients in the control group had missing data 
for 90-day modified Rankin Scale scores. Patients with 
missing follow-up data were censored from analyses of 
the primary endpoint and secondary endpoints that were 
assessed at 90 days after symptom onset. Patients in the 
intervention and control groups enrolled within 3 h of 
symptom onset did not differ in terms of modified Rankin 
Scale scores at 90 days (adjusted cOR 1·05, 95% CI 
0·77–1·45; p=0·74; table 2; figure 2). Moreover, modified 
Rankin Scale scores at 90 days in patients enrolled within 
4·5 h (secondary global outcome) did not differ between 
the intervention and control groups (adjusted cOR 1·06, 
95% CI 0·80–1·42; p=0·67; table 2). We also detected no 
difference between groups in modified Rankin Scale 
scores at 90 days in patients enrolled within 3 h of 
symptom onset after adjusting for per-protocol defined 
covariates (site, baseline NIHSS, premorbid modified 
Rankin Scale score, and age) in the statistical analysis plan 
(adjusted cOR 0·93, 95% CI 0·69–1·24; p=0·61; data not 
shown). Furthermore, no difference was noted in the 
Figure 2: Modified Rankin Scale scores at 90 days in patients treated with intravenous thrombolysis within 
3 h (intention-to-treat population)
Scores on the modified Rankin Scale range from 0 to 6, with 0 indicating no symptoms, 1 no clinically significant 
disability, 2 slight disability (patient is able to look after own affairs without assistance but is unable to carry out all 
previous activities), 3 moderate disability (patient requires some help but is able to walk unassisted), 4 moderately 
severe disability (patient is unable to attend to bodily needs without assistance and unable to walk unassisted), 
5 severe disability (patient requires constant nursing care and attention), and 6 death.
Control group (n=341)
Intervention group (n=335)
Proportion of patients (%)
14·2% 16·5% 15·7% 14·6% 17·3% 6·7% 15%
14·1% 18% 17·6% 10·6% 17·3% 5·1% 17·3%
60200 1008040
1 20 3 4 5 6
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adjusted analyses of modified Rankin Scale score at 
90 days in patients enrolled within 3 h of symptom 
onset using either multiple imputation methodology 
(unadjusted cOR 0·98, 95% CI 0·73–1·31; p=0·87; 
adjusted cOR 0·99, 95% CI 0·74–1·34; p=0·97; appendix) 
or imputation to the worst case (un adjusted cOR 1·08, 
95% CI 0·80–1·45; p=0·60; adjusted cOR 1·14, 95% CI 
0·84–1·54; p=0·39; appendix). The intervention and 
control groups did not differ with respect to any secondary 
outcomes (table 2). 
The safety population comprised 317 patients in the 
intervention group and 329 in the control group. 51 (16%) 
patients assigned to the intervention group and 44 (13%) 
assigned to the control group died (unadjusted OR 1·24, 
95% CI 0·80–1·92; p=0·37) and 83 (26%) and 79 (24%) 
patients, respectively, had serious adverse events (un-
adjusted OR 1·12, 95% CI 0·79–1·60; p=0·53; table 3). 
The occurrence of symp tomatic intracranial haemorrhage 
did not differ between the intervention and control 
groups at 24 h (eight [3%] of 317 patients vs six [2%] of 
329 patients; unadjusted OR 1·39, 95% CI 0·48–5·06; 
p=0·60) or at 36 h (nine [3%] of 317 patients vs seven [2%] 
of 329 patients; 1·34, 0·49–3·65; p=0·62). The only safety 
outcome that differed between treatment groups was 
asymptomatic intracranial haemorrhage at 24 h, which 
was more prevalent in the inter vention group than  in the 
control group (34 [11%] of 317 patients vs 20 [6%] of 
329 patients; unadjus ted OR 1·86, 95% CI 1·04–3·30; 
p=0·046), but after adjustment for baseline NIHSS score, 
age, base line serum glucose, and time to alteplase bolus, 
this difference became non-significant. The only adverse 
event that differed between intervention and control 
groups was atrial fibrillation (28 [9%] of 317 patients vs 
14 [4%] of 329 patients; unadjusted OR 2·18, 95% CI 
1·12–4·22; p=0·025). However, after excluding patients 
with atrial fibrillation at baseline assessment, this dif-
ference be came non-significant (23 [7%] of 312 patients 
vs 13 [4%] of 328 patients; unadjusted OR 1·93, 95% CI 
0·96–3·88; p=0·085). Two (1%) of 317 patients in the 
intervention group had partial seizures compared with 
no patients in the control group (OR 5·22, 95% CI 
0·25–109·20; p=0·49).
We did not detect any differences (p≥0·1 for interaction) 
in the effect of sonothrombolysis in prespecified sub-
group analyses by sex, age, baseline NIHSS score, and 
time from symptom onset to alteplase bolus (figure 3). 
Sensitivity analyses did not detect any difference in 
primary and secondary efficacy outcomes, mortality, or 
symptomatic intracranial haemorrhage after excluding 
patients with 90-day modified Rankin Scale scores after 
completion of the second interim analysis (47 patients in 
the intervention group and 52 in the control group). 
Further details on sensitivity analyses are in the appendix. 
Analyses of efficacy outcomes in the per-protocol and 
safety populations yielded similar results to analyses 
in the intention-to-treat population (appendix). Similarly, 
analyses of safety outcomes yielded almost identical 
results in the intention-to-treat population, per-protocol 
population, and safety population (appendix).
Discussion
The CLOTBUST-ER trial was stopped early because of 
futility, according to prespecified rules. Findings of the 
trial showed that, compared with standard-of-care treat-
ment alone (alteplase bolus), additional use of low-power 
high-frequency ultrasound with an operator-independent 
device provided no benefit for functional outcome. 
However, the results indicated the potential feasibility 
and safety of sonothrombolysis for patients with acute 
ischaemic stroke.
Our findings regarding sonothrombolysis safety 
cor roborate the conclusions of two independent meta-
analyses suggesting the potential safety of high-frequency 
ultra sound coupled with intravenous thrombolysis as an 









p value Adjusted OR 
(95% CI)
p value 
Death 51 (16%) 44 (13%) 1·24 (0·80–1·92) 0·37 1·19 (0·74–1·92) 0·48
Death due to serious 
adverse event
34 (11%) 34 (10%) 1·04 (0·63–1·72) 0·90 1·00 (0·58–1·73) >0·99
Serious adverse 
events
83 (26%) 79 (24%) 1·12 (0·79–1·60) 0·53 1·08 (0·74–1·57) 0·69
Symptomatic 
intracranial 
haemorrhage at 24 h
8 (3%) 6 (2%) 1·39 (0·48–5·06) 0·60 1·43 (0·49–4·44) 0·51
Symptomatic 
intracranial 
haemorrhage at 36 h
9 (3%) 7 (2%) 1·34 (0·49–3·65) 0·62 1·39 (0·51–3·95) 0·52
Asymptomatic 
intracranial 
haemorrhage at 24 h
34 (11%) 20 (6%) 1·86 (1·04–3·30) 0·046 1·78 (0·98–3·31) 0·061
Cerebral oedema 17 (5%) 8 (2%) 2·27 (0·97–5·35) 0·066 2·15 (0·93–5·40) 0·08
Brain herniation 11 (3%) 5 (2%) 2·33 (0·80–6·78) 0·13 2·09 (0·73–6·87) 0·19




21 (7%) 22 (7%) 0·99 (0·53–1·84) >0·99 1·01 (0·53–1·96) 0·96
Headache 57 (18%) 50 (15%) 1·22 (0·81–1·85) 0·40 1·30 (0·85–2·00) 0·23
Pyrexia 30 (9%) 37 (11%) 0·82 (0·50–1·37) 0·52 0·81 (0·48–1·36) 0·43




34 (11%) 27 (8%) 1·34 (0·79–2·28) 0·28 1·33 (0·76–2·36) 0·32
Constipation 24 (8%) 33 (10%) 0·73 (0·42–1·27) 0·33 0·69 (0·39–1·20) 0·19
Atrial fibrillation as 
adverse event
28 (9%) 14 (4%) 2·18 (1·12–4·22) 0·025 2·25 (1·17–4·52) 0·018
Atrial fibrillation as 
adverse event after 
exclusion of patients 
with atrial fibrillation 
at baseline
23/312 (7%) 13/328 
(4%)
1·93 (0·96–3·88) 0·085 1·91 (0·96–3·97) 0·072
OR=odds ratio. 
Table 3: Safety outcomes and serious adverse events within 90 days after randomisation in the safety 
population
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stroke.8,9 The proportion of patients in the inter vention 
group of CLOTBUST-ER with symptomatic intra cranial 
haemorrhage (3% at 36 h) is less than the pooled pro-
portion reported in previous smaller ran dom ised con-
trolled trials of sonothrombolysis (4%),8 but it is similar 
to data reported in the European Cooperative Acute 
Stroke Study III (2%)2 and the Safe Implementation of 
Thrombolysis in Stroke-Monitoring Study (2%).17 More-
over, the proportion with symptomatic intracranial 
haemorrhage was lower than the proportion reported in an 
individual patient data meta-analysis of nine intra venous 
thrombolysis trials (4%),20 despite the fact that pretreatment 
stroke severity was higher in our trial.
A potential safety concern in our trial was the high 
proportion of patients with cerebral oedema, brain 
herniation, and asymptomatic intracranial haemorrhage 
detected in the intervention group in unadjusted analyses 
(table 3). These adverse events were recorded based 
on radiology reports by local investigators, without 
undergoing central adjudication. In previous random-
ised controlled trials, no association was detected 
between ultrasound-enhanced thrombolysis and risk for 
cerebral oedema.7,21,22 Likewise, contrary to symptomatic 
intracranial haemorrhage, asymptomatic intracranial 
haemorrhage is not related to clinical outcome in patients 
treated with intravenous thrombolysis.23 Moreover, the 
proportions of patients with midline shift were similar in 
the intervention and control groups of CLOTBUST-ER, 
and no difference was noted between treatment groups in 
neurological deterioration at 24 h. Finally, associations of 
sonothrombolysis with cerebral oedema, brain herniation, 
and asymptomatic intracranial haemorrhage were not 
significant after adjustment for prespecified con founders. 
Nevertheless, the potential relation between 2 MHz 
sonothrombolysis and cerebral oedema deserves further 
investigation in future randomised controlled trials with 
central adjudication of brain herniation.
Sonothrombolysis did not improve functional outcome 
in CLOTBUST-ER. This finding could be partly explained 
by design features and limitations of our trial. First, unlike 
previous studies of ultrasound-enhanced thrombolysis, in 
which imaging documentation of proximal intracranial 
occlusions was required,7,21,22 stroke severity was used 
as the surrogate measure of large-vessel occlusion and 
vascular imaging was not mandatory. As a result, some of 
our patients might not have had a proximal occlusion 
within the target area of our operator-independent device. 
We postulate that our findings parallel the results of the 
Interventional Management of Stroke III (IMS III) trial,24 
which confirmed the need to select patients with a 
proximal arterial occlusion using vessel imaging to 
test acute reperfusion treatments (instead of enrolling 
patients with severe stroke as a surrogate for an occlusion). 
Second, compared with use of a handheld device in 
previous positive studies,7,8 it is possible that our operator-
inde pendent device provided less direct thrombus 
exposure to ultrasound because of the multitransducer 
head frame design.25,26 Third, data for functional out-
come at 90 days were unavailable in 63 patients (9% of 
the study population), because of early discontinuation 
of CLOTBUST-ER after the second interim analysis. 
After study termination by the funder, 90-day follow-up 
assessments were completed for most patients because of 
the efforts of onsite investigators, who were asked to 
complete the trial in their own time. Nevertheless, it 
should be noted that our sensitivity analysis indicated 
that there was no difference in safety and efficacy out-
comes after exclusion of patients with documentation of 
their 90-day functional status after the second interim 
analysis. Furthermore, we formally tested and verified the 
randomn ess of the missing follow-up data in exploratory 
analyses. Fourth, potential enrol ment bias at some sites—
arising from higher priority given to endovascular treat-
ment options—might have led to enrolment of fewer 
large-vessel occlusions at those centres.
Our study has other limitations, including the non-
significant difference in time from symptom onset to 
treatment in favour of the intervention group (117 min vs 
126 min in the control group) and reliance on the 
investigator’s ability to properly mount the device and gel 
pads without any further onsite validation being done. 
We should also highlight the paucity of prospectively 
gathered data for ischaemic stroke aetiological classifica-
tion or anatomic localisation and, therefore, our inability 
to do additional subgroup analyses for patients with 
lacunar versus non-lacunar strokes and patients with 
anterior versus posterior circulation strokes. Further, 
only 38 patients were enrolled in the designed arterial 
recanalisation substudy (based on pretreatment and post-
treatment CT angiography), and we were unable to assess 
Figure 3: Common odds ratio for improvement on the modified Rankin Scale at 90 days in patients treated 
with intravenous thrombolysis within 4·5 h
Data were analysed according to ordinal logistic regression after collapsing modified Rankin Scale scores 5 and 6 
and adjusting for age, NIHSS score at baseline, time from stroke onset to alteplase bolus, and baseline serum 
glucose, across the different prespecified subgroups. NIHSS scores range from 0 to 42, with higher scores 
indicating more severe neurological deficits. Thresholds for age and NIHSS score were chosen at the median. 
The threshold for time from stroke onset to alteplase bolus was prespecified. cOR=common odds ratio. 
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the effect of sonothrombolysis on recanalisation and 
functional outcome of patients with acute ischaemic stroke 
with large-vessel occlusions. The steering committee 
decided not to make vascular imaging mandatory for 
patients’ inclusion because some participating centres did 
not have CT angiography available 24 h a day 7 days a week, 
and because round-the-clock availability of CT angiography 
was not part of standard-of-care treatment at the time of 
study design. Moreover, we decided to implement a similar 
approach to the IMS III trial,24 to identify patients with 
large-vessel occlusions using a cutoff for the NIHSS score 
of 10 points or greater. Unfortunately, the negative results 
of IMS III could not be predicted during CLOTBUST-ER 
design and initiation.
In view of the positive results of recent thromb-
ectomy trials (highlighting CT angiography as part of 
standard-of-care treatment), we have redesigned the 
operator-independent ultrasound device to target CT 
angiography-located large-vessel occlusions with only 
one set of transducers that will be placed either over the 
right or left temporal window or sub occipitally dependent 
on occlusion location seen on CT angiography. The 
redesigned device will also use novel coupling gel pads to 
achieve improved headframe fixa tion during insonation. 
This new device will be tested in the TRUST trial 
(NCT03519737), in which all patients with large-vessel 
occlusions who meet standard criteria for intravenous 
alteplase and who are being transferred from primary to 
comprehensive stroke centres will be randomised to 
either ultrasound or no ultrasound, with the primary 
endpoint being recanalisation at receiv ing hospitals on 
digital subtraction angiography before thrombectomy. 
Finally, it should be mentioned that the study was 
terminated by the funder, and no additional funding was 
available after completion of the follow-up of enrolled 
patients. The lengthy process of report preparation was 
the main reason for delaying publication of the study 
findings, which were presented in part at the European 
Stroke Organisation Conference in Barcelona in 2016.
Our experience in CLOTBUST-ER suggests that the 
increasing implementation of endovascular treatments 
across major academic stroke centres will present chal-
lenges for clinical trials aiming to test non-interventional 
or adjuvant reperfusion strategies. The potential effective-
ness of sonothrombolysis might be further investigated in 
randomised controlled trials undertaken in stroke centres 
that are dependent on transfer of patients for endovas-
cular reperfusion treat ments or in countries where these 
therapies cannot yet be offered as standard of care.
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